US › Healthcare

Kailera Therapeutics, Inc. Common Stock (KLRA)

US · Healthcare · Biotechnology

$18.11+4.56%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-78.9M

EPS

$-3.65

EPS estimate

$-0.55

EPS came in at -3.65 against a street estimate of -0.55 — a miss of 563.6%.

Key statistics

Market cap

$2.19B

Forward P/E

0.0

P/B

0.00

Book value

$-14,425.53

EPS (TTM)

$-1.78

52-week high

$28.23

52-week low

$16.00

50-day MA

$20.13

200-day MA

$21.13

Analyst view

with an average price target of $42.60.

Shareholding

Institutions

47.20%

Largest institutional holders

Fund	Stake
Exchange Traded Concepts, LLC	0.12%
Tema ETFs	0.01%

Recent filings & reports

Document	Date
Quarterly report · Q1 2026	2026-05-26
Results announced · Q2 2026	2026-05-26
Charter / bylaws change · Q2 2026	2026-04-20

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kailera Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.